QNCX
Quince Therapeutics, Inc.
NASDAQ: QNCX · HEALTHCARE · BIOTECHNOLOGY
$1.31
+6.50% today
Updated 2026-04-30
Market cap
$20.05M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-16.80
Dividend yield
—
52W range
$1 – $46
Volume
63.6M
Quince Therapeutics, Inc. (QNCX) Financial statements
SEC filings — annual and quarterly data.
Profit margin
0.00%
Operating margin
0.00%
ROE
-247.80%
ROA
-30.30%
Debt/equity
16.99x
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2017 | — | $-12.23M | — | — | — |
| 2018 | $0.00 | $-12.48M | — | — | — |
| 2019 | $0.00 | $-36.98M | — | — | — |
| 2020 | $0.00 | $-76.85M | — | — | — |
| 2021 | $0.00 | $-89.94M | — | — | — |
| 2022 | $0.00 | $-51.66M | — | — | — |
| 2023 | $0.00 | $-31.39M | — | — | — |
| 2024 | $0.00 | $-56.83M | — | — | — |
| 2025 | $0.00 | $-83.98M | — | — | — |